Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses β-catenin-dependent transcription

Mutated in colorectal cancer (MCC) was originally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP and the physiologic/pathologic roles of MCC remained poorly understood. Recently, MCC promoter methylation was discovered as a frequent early event in a distinct subset of precursor lesions and colorectal cancer (CRC) associated with the serrated CRC pathway. Here we provide the first evidence of the biological significance of MCC loss in CRC and the molecular pathways involved. We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAFV600E mutation due to promoter methylation as reported previously. Importantly, we find MCC interacts with β-catenin and that reexpression of MCC in CRC cells specifically inhibits Wnt signaling, β-catenin/T-cell factor/lymphoid-enhancer factor-dependent transcription and cellular proliferation even in the presence of oncogenic mutant APC. We also show that MCC is localized in the nucleus and identify two functional nuclear localization signals. Taken together, MCC is a nuclear, β-catenin-interacting protein that can act as a potential tumor suppressor in the serrated CRC pathway by inhibiting Wnt/β-catenin signal transduction.

[1]  D. Seminara,et al.  Ascending the learning curve--MSI testing experience of a six-laboratory consortium. , 2006, Cancer biomarkers : section A of Disease markers.

[2]  G. Casey,et al.  Role of IKK and oscillatory NFκB kinetics in MMP‐9 gene expression and chemoresistance to 5‐fluorouracil in RKO colorectal cancer cells , 2007, Molecular carcinogenesis.

[3]  H. Clevers,et al.  Wnt signaling in the intestinal epithelium: from endoderm to cancer. , 2005, Genes & development.

[4]  K. Kinzler,et al.  Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. , 1991, Science.

[5]  G. Stark,et al.  Distinct Roles of the IκB Kinase α and β Subunits in Liberating Nuclear Factor κB (NF-κB) from IκB and in Phosphorylating the p65 Subunit of NF-κB* , 2001, The Journal of Biological Chemistry.

[6]  B. Leggett,et al.  APC mutation and tumour budding in colorectal cancer , 2003, Journal of clinical pathology.

[7]  T. Akiyama,et al.  Localization of MCC (Mutated in Colorectal Cancer) in Various Tissues of Mice and Its Involvement in Cell Differentiation , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  M. Loda,et al.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. , 2006, The Journal of molecular diagnostics : JMD.

[9]  R. White,et al.  MCC, a candidate familial polyposis gene in 5q.21, shows frequent allele loss in colorectal and lung cancer. , 1991, Oncogene.

[10]  A. Hirai,et al.  Interaction of MCC2, a novel homologue of MCC tumor suppressor, with PDZ-domain Protein AIE-75. , 2001, Gene.

[11]  L. Terracciano,et al.  Role of APAF‐1, E‐cadherin and peritumoural lymphocytic infiltration in tumour budding in colorectal cancer , 2007, The Journal of pathology.

[12]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Minoru Yoshida,et al.  Nuclear Export of Human β-Catenin Can Occur Independent of CRM1 and the Adenomatous Polyposis Coli Tumor Suppressor* , 2001, The Journal of Biological Chemistry.

[14]  M. Karin,et al.  Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. , 2004, Cancer cell.

[15]  H. Ueno,et al.  Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays , 2005, Laboratory Investigation.

[16]  J. Ninomiya-Tsuji,et al.  Regulation of Lymphoid Enhancer Factor 1/T-Cell Factor by Mitogen-Activated Protein Kinase-Related Nemo-Like Kinase-Dependent Phosphorylation in Wnt/β-Catenin Signaling , 2003, Molecular and Cellular Biology.

[17]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[18]  B. Henderson.  Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover , 2000, Nature Cell Biology.

[19]  C. Ostwald,et al.  High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. , 2007, Human pathology.

[20]  G. Casari,et al.  A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. , 2004, Nature cell biology.

[21]  Avri Ben-Ze'ev,et al.  Autoregulation of E-cadherin expression by cadherin–cadherin interactions , 2003, The Journal of cell biology.

[22]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[23]  T. Akiyama,et al.  MCC, a Cytoplasmic Protein That Blocks Cell Cycle Progression from the G/G to S Phase (*) , 1996, The Journal of Biological Chemistry.

[24]  G. Casey,et al.  The AKT/IκB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κB and β-catenin , 2005, Oncogene.

[25]  G. Casey,et al.  The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. , 2005, Oncogene.

[26]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[27]  Seth G. N. Grant,et al.  PDZ Domain Proteins: Plug and Play! , 2003, Science's STKE.

[28]  R. Kucherlapati,et al.  Mouse models for colorectal cancer , 1999, Oncogene.

[29]  P. Laird,et al.  Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer , 2007, Oncogene.

[30]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[31]  Mariann Bienz,et al.  The APC tumour suppressor has a nuclear export function , 2000, Nature.

[32]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[33]  G. Stark,et al.  Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. , 2002, The Journal of biological chemistry.

[34]  B. Leggett,et al.  Emerging concepts in colorectal neoplasia. , 2002, Gastroenterology.

[35]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[36]  Hans Clevers,et al.  The TAK1–NLK–MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF , 1999, Nature.

[37]  J. Jass,et al.  Serrated adenoma of the colorectum , 2002 .

[38]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.